{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:07:39Z","timestamp":1762013259785,"version":"build-2065373602"},"reference-count":4,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jaad.2019.04.025","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T11:35:41Z","timestamp":1555414541000},"page":"e139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reply to: Comment on \u201cBullous pemphigoid and neuropsychiatric medications: An influence of drugs or of underlying conditions?\u201d"],"prefix":"10.1016","volume":"88","author":[{"given":"Outi","family":"Varpuluoma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jari","family":"Jokelainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaisa","family":"Tasanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Huilaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2019.04.025_bib1","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.jaad.2019.03.091","article-title":"Bullous pemphigoid and neuropsychiatric medications: an influence of drugs or of underlying conditions?","volume":"88","author":"Kridin","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.04.025_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaad.2019.02.017","article-title":"Drugs used for neurological and psychiatric conditions increase the risk of bullous pemphigoid: a case-control study","volume":"81","author":"Varpuluoma","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.04.025_bib3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/exd.13401","article-title":"Neurological and psychiatric associations in bullous pemphigoid\u2013more than skin deep?","volume":"26","author":"F\u00f6rsti","year":"2017","journal-title":"Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.04.025_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219306127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219306127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:09:19Z","timestamp":1759273759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219306127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":4,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0190962219306127"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.04.025","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to: Comment on \u201cBullous pemphigoid and neuropsychiatric medications: An influence of drugs or of underlying conditions?\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.03.091","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}